Clear Street Remains a Buy on Summit Therapeutics (SMMT)

Tip Ranks
2025.11.07 18:56
portai
I'm PortAI, I can summarize articles.

Clear Street analyst William Maughan has maintained a Buy rating on Summit Therapeutics (SMMT) with a price target of $32.00. Maughan, who specializes in the Healthcare sector, has an average return of 19.8% and a success rate of 46.81% on his stock recommendations. The analyst consensus for Summit Therapeutics is a Moderate Buy, with a price target consensus of $30.55.

Clear Street analyst William Maughan maintained a Buy rating on Summit Therapeutics today and set a price target of $32.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Maughan covers the Healthcare sector, focusing on stocks such as BioNTech SE, Summit Therapeutics, and Wave Life Sciences. According to TipRanks, Maughan has an average return of 19.8% and a 46.81% success rate on recommended stocks.

Summit Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $30.55.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer